These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 7000978)

  • 1. Lecithin in Parkinson's disease.
    Barbeau A
    J Neural Transm Suppl; 1980; (16):187-93. PubMed ID: 7000978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difficulties in long term management of Parkinson's disease.
    Burns R
    Aust Fam Physician; 1984 May; 13(5 Suppl):14-6. PubMed ID: 6497765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Depressive pseudodementia in early Parkinson's disease: lessons from a case with long-term follow-up].
    Giménez-Roldán S; Mateo D; Dobato JL
    Neurologia; 1997 Mar; 12(3):130-5. PubMed ID: 9198454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E; González M; Aguilar A; Quintana S
    Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuropsychiatric disorders in Parkinson's disease].
    Noé-Sebastián E; Irimia-Sieira P; Pomares-Arias E; Martínez-Vila E; Luquin-Piudo MR
    Rev Neurol; 2001 Apr 1-15; 32(7):676-81. PubMed ID: 11391498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
    Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
    Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of consumption of choline and lecithin on neurological and cardiovascular systems.
    Wood JL; Allison RG
    Fed Proc; 1982 Dec; 41(14):3015-21. PubMed ID: 6754453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecithin treatment of cognitively impaired Parkinson's patients.
    Tweedy JR; Garcia CA
    Eur J Clin Invest; 1982 Feb; 12(1):87-90. PubMed ID: 6802657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here?
    Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487
    [No Abstract]   [Full Text] [Related]  

  • 18. Confusion, dementia and anticholinergics in Parkinson's disease.
    de Smet Y; Ruberg M; Serdaru M; Dubois B; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1982 Dec; 45(12):1161-4. PubMed ID: 7161613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticholinergic-induced analgesia: possible role for the cholinergic system in abnormal sensory symptoms in Parkinson's disease.
    Sandyk R
    Postgrad Med J; 1986 Aug; 62(730):749-51. PubMed ID: 2430273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary lecithin supplements in dementia of Alzheimer type.
    Perry EK; Perry RH; Tomlinson BE
    Lancet; 1977 Jul; 2(8031):242-3. PubMed ID: 69845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.